Archives

– AMPLIVANT™ TLR-ligand adjuvant to improve immunotherapies –

Leiden, The Netherlands, April 9, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, announces that Cornelis Melief, Professor at Leiden University and Chief Scientific Officer of ISA, presented details on the company’s novel AMPLIVANT™ technology at the American Association for Cancer Research (AACR) 2013 Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand designed to improve immunotherapies. This promotes direct dendritic cell targeting of the antigen as well as antigen processing, resulting in long-term activation of

Leiden, The Netherlands, April 2, 2013 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT™ platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.

Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“
Symposium: SY27 “New Cancer Vaccines“
Abstract number: SY27-01
Date: April 9, 2013, at 10:40 a.m.
Location: Room 202 at the Washington Convention Center.

The abstract is available at the AACR